RxDoctor Payments Data

Mya Levy, MD

Urology · Porter Ranch, CANPI 1205132628

Payments from drug & device makers

$3,745in general payments, 2019–2025

Across 128 payments — averaging $29.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Coloplast$735
  • Axonics, Inc.$467
  • Boston Scientific$178
  • Procept Biorobotics Corporation$145
  • Neotract Inc.$124
  • plus $296 from 9 others

What the payments were for

  • Travel & lodging$1,14431%
  • Food & beverage$2,31162%
  • Education$2908%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic(2 entities)39$1,800
Coloplast63$735
Axonics, Inc.4$467
Boston Scientific4$178
Procept Biorobotics Corporation2$145
Neotract Inc.1$124
Tolmar Pharmaceuticals, Inc.3$65
AbbVie(2 entities)3$64
Astellas Pharma US Inc3$54
Urogen Pharma, Inc.1$25
Sobi, Inc1$20
Sumitomo Pharma America, Inc.1$19
Olympus America Inc.1$19
Metuchen Pharmaceuticals1$17
Avadel Specialty Pharmaceuticals, LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,745 in reported general payments places this provider in the 55th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$83,508
Medicare patients
154
Services billed
2,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron281$189,604
MyrbetriqMirabegron147$96,512
PremarinEstrogens, Conjugated72$32,365
Tamsulosin Hcl178$3,082
Finasteride229$2,814
YuvafemEstradiol14$2,329
Methenamine Hippurate21$1,743
Estradiol25$1,524
Oxybutynin Chloride ErOxybutynin Chloride41$1,355
Cefdinir88$892
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst62$836
Cefpodoxime Proxetil17$572
Doxazosin Mesylate25$404
Cephalexin42$239
Ciprofloxacin Hcl66$207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$19$189,604281 claims
Astellas Pharma US IncMyrbetriq$54$96,512147 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,324 urology providers in California.

Other urology in Porter Ranch

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →